Feb 11, 2013 by Brenton FlynnNovo Nordisk Fails, Sanofi and Lilly WinThe FDA needs more data to give these diabetes drugs the go-ahead.
Feb 10, 2013 by Brenton FlynnHow Long Can This Pharma Gold Rush Last?High priced orphan drugs are garnering a lot of attention.
Feb 8, 2013 by Brenton FlynnAn Unsurprising Pipeline FailureEli Lilly pulls the plug on this pipeline program.
Feb 8, 2013 by Brenton FlynnAn Obesity Treatment Doomed for Failure?There's nothing blocking this sell-off.
Feb 7, 2013 by Brenton FlynnWill the FDA Give These Drugs a Thumbs Up?Two drugs with big decisions coming up. Will they be approved?
Feb 7, 2013 by Brenton FlynnThe "Real" Opportunity for Health CareTwo of the U.S.'s biggest pharmacy benefit managers are making moves in Brazil.
Feb 7, 2013 by Brenton FlynnWill the FDA Give This Drug the Green Light?An FDA approval decision approaches for Celgene.
Feb 6, 2013 by Brenton FlynnUp 25%, the Anti-Dentite's Nightmare Stock SurgesHold still, I need to stick this laser in your mouth.
Feb 6, 2013 by Brenton Flynn1 Reason Dendreon Continues to March HigherThe stock was priced to die, but Dendreon has shown a few signs of life.
Feb 6, 2013 by Brenton FlynnThe Hole in AbbVie's 2013The loss of AbbVie's second best seller will weigh on sales this year
Feb 4, 2013 by Brenton FlynnShould You Buy Merck After This Selloff?There's no question that Merck is cheap
Feb 4, 2013 by Brenton FlynnHumana Surges on Earnings UpsideHumana shares popped on earnings release.
Feb 4, 2013 by Brenton FlynnA Dark Cloud Is Lifted From CyberonicsThe dismissal of a major lawsuit helps Cyberonics shares surge higher
Feb 4, 2013 by Brenton FlynnHyperion Surges on FDA Approval, but What's Next?A follow on indication for RAVICTI will be a key area to watch for Hyperion shareholders.
Feb 4, 2013 by Brenton FlynnWhat to Make of Questcor ManagementWhat do we really think of the management team at Questcor?
Jan 30, 2013 by Brenton FlynnWhat Questcor Investors Absolutely Must WatchThe most important things for Questcor investors to be following right now.
Jan 25, 2013 by Brenton FlynnBreaking Down Health Care's Biggest Earnings ReportMotley Fool bureau chief Brenton Flynn discusses his key takeaways from the most notable health care industry earnings reports.
Jan 25, 2013 by Brenton FlynnShould You Replace This Joint Replacement Specialist?Motley Fool bureau chief Brenton Flynn discusses his key takeaways from the most notable health care industry earnings reports.
Jan 25, 2013 by Brenton FlynnA Key Earnings Report in Cardiac Medical DevicesMotley Fool bureau chief Brenton Flynn discusses his key takeaways from the most notable health care industry earnings reports.
Jan 25, 2013 by Brenton FlynnAbbott Labs -- Not AbbVie -- Is Acting Like a SpinoffMotley Fool bureau chief Brenton Flynn discusses his key takeaways from the most notable health care industry earnings reports.
